Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based CFO’ operating in the Medical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Lee Kalowski
Chief Financial Officer of Bicycle Therapeutics
Lee has served as chief financial officer at Tokai since September 2014. Prior to joining Tokai, he served as a vice president in global biotechnology equity research at Credit Suisse. In this role, Lee served as a senior research analyst covering the biotechnology industry, including numerous companies globally in the prostate cancer therapeutic area. Prior to Credit Suisse, Lee worked at Johnson & Johnson in mergers & acquisitions in the pharmaceutical group, where he was involved in the analysis and execution of several completed transactions, and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Lee holds a B.A., Phi Beta Kappa, in biology and economics, from Union College and an M.B.A. in finance and health care management from the Wharton School, University of Pennsylvania.
Follow Lee Kalowski:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Jeanne Henry
CFO of Excel Venture Management
Jeanne joined the Excel team in 2009 and brings more than 18 years of venture capital financial management and reporting experience to the team. Previously, Jeanne was CFO and most recently COO with Atlas Venture, an international venture firm. Earlier she was an Audit Manager with Coopers & Lybrand (now PricewaterhouseCoopers). Jeanne holds a B.A. from the University of New Hampshire, an MBA from the University of Illinois, Chicago and is a Certified Public Accountant. She is a member of the AICPA, the M.A. Society of CPA’s, and a former Board member of the Private Equity CFO Association.
Follow Jeanne Henry:
About Excel Venture Management: Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond.
Kevin Gillis
CFO / Partner of Third Rock Ventures
Kevin Gillis joined Third Rock Ventures in 2008 and oversees the operational, financial and administrative aspects of the firm. He also directs and oversees the initial operational activities for our portfolio companies. Kevin has approximately 20 years of financial experience, successfully designing, overseeing and managing the financial operations for both newly emerging and established biotech companies. Prior to joining Third Rock Ventures, Kevin was Vice President of Finance at Coley Pharmaceutical Group, supporting the company’s successful initial public offering in 2005 and overseeing the finances related to the company’s acquisition by Pfizer in 2008. Prior to Coley, Kevin served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company. Kevin holds an MBA from Bentley University and a BA from Brandeis University.
Follow Kevin Gillis:
About Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Linda C. Bain
CFO of Codiak Biosciences
Linda C. Bain, CPA, has served as our vice president of finance and business operations since October 2011 and as our treasurer since March 2013. Previously, she served as vice president of corporate finance at Genzyme from September 2008 to September 2011, at Fidelity Investments from September 2007 to September 2008 and a number of positions at AstraZeneca from May 2000 to September 2007. She received her B.S. from the University of the Orange Free State in South Africa.
Follow Linda C. Bain:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Diane Marcou
Consulting CFO of Satellite Bio
Ms. Marcou has provided financial and strategic advisory services to a number of venture-backed technology companies, including ByAllAccounts, Inc., Fluidnet Corporation, Radianse and T2 Biosystems. Prior to working as an independent financial consultant, she was Chief Financial Officer and Vice President of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technologies, a publicly traded software company with domestic and international operations. Ms. Marcou earned a B.S. in Business Administration from Boston College, and her CPA from PricewaterhouseCoopers, formerly Coopers & Lybrand.
Follow Diane Marcou:
About Boston MicroFluidics, Cytrellis Biosystems, Incentive Systems, Satellite Bio, Workgroup Technology: Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.
Peter Aranow
Chief Financial Officer of Respiratory Motion
Mr. Aranow is the Chairman of Boynton Angels, a Worcester investor group that invests in start-up companies. Peter Aranow has spent 30 years in finance. For 17 years he was in the investment banking department of Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies, including an Internet advertising company and the New York City Off-Track Betting Corporation. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.
Follow Peter Aranow:
About Harvard Business School Community Action Partners, Off Track Betting New York, Respiratory Motion: Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
Kimi Iguchi
CFO of SAGE Therapeutics
Kimi Iguchi joined SAGE Therapeutics in March 2013 as Chief Financial Officer with more than 15 years of progressive experience managing finance, accounting, operations and human resources in emerging life science companies. Prior to joining SAGE, Ms. Iguchi has led the organizational development of strategic business plans, portfolio management, deal structure, fund raising, financial planning, and operations infrastructure design and growth. She has held positions at Warp Drive Bio, LLC, Santhera Pharmaceuticals, Cyberkinetics, Millennium Pharmaceuticals and Biogen, Inc. She began her career at PricewaterhouseCoopers LLP, Boston. Ms. Iguchi holds a B.A. in chemistry from Drew University, received her MBA from Northeastern University, and earned her CPA in Massachusetts.
Follow Kimi Iguchi:
About SAGE Therapeutics: SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Steve Maiocco
Chief Financial Officer of Schooner Capital
Steve has been Schooner’s Chief Financial Officer since 1996. A Managing Director, Steve divides his time between Schooner’s internal financial and administrative matters and Schooner’s investment portfolio, including serving as a board member of Millstone Medical Outsourcing and Iron Rail Group. Prior to joining Schooner, Steve spent approximately fourteen years in public accounting at Tonneson & Company CPAs P.C. where he worked with his clients on a wide range of accounting, financial and tax matters. Steve has an undergraduate degree from Cornell University and a Master’s of Science in Taxation degree from Bentley University. He is also licensed as a Certified Public Accountant in the Commonwealth of Massachusetts.
Follow Steve Maiocco:
About Schooner Capital: Schooner Capital is a Boston-based private investment firm engaged in venture capital, growth equity, and public securities.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
David Murray
Chief Financial Officer of Alcon
Follow David Murray:
About Alcon: Alcon specializes in developing and manufacturing innovative medicines and devices to serve the full life cycle of eye care needs.
Will Rousmaniere
Chief Financial Officer of Analogic
Will joined Analogic in 2012 as finance director for the company’s Ultrasound Business. In 2015 he was named senior director, financial planning and analysis. Prior to joining Analogic, Will was director of finance, precision motion and technologies at GSI Group (now Novanta), and held multiple financial leadership roles at Varian Semiconductor Equipment Associates (now a division of Applied Materials) as well as financial and operational roles at a number of technology start-ups. He earned an MBA in finance and accounting from New York University, Stern School of Business, and a BA in Economics from Cornell University and was a Certified Public Accountant.
Follow Will Rousmaniere:
About Analogic: Analogic is a technology company that develops computed tomography, ultrasound, digital mammography, and magnetic resonance imaging systems.
Genevieve Barnard
CFO & Co-Founder of MDaaS Global
Genevieve Barnard is the CFO and Co- founder of MDaaS. She used to be the associate director of associate director at Kletjian Foundation. Genevieve earned her MBA at Massachusetts Institute of Technology – Sloan School of Management.
Follow Genevieve Barnard:
About MDaaS Global: MDaaS Global operates tech-enabled diagnostic centers in clinically-underserved communities.
Dan Krzmarzick
CFO of Patientco
Dan Krzmarzick serves as CFO at Patientco.
Follow Dan Krzmarzick:
About Patientco: Patientco improves financial care across the entire patient journey while increasing payments and revenue for today’s top health systems.
Daniella Beckman
CFO of Tango Therapeutics
Daniella Beckman has served as the senior vice president, chief financial officer and treasurer of Idenix since March 2012 and the vice president, chief financial officer and treasurer since June 2011. Daniella Beckman served as the interim chief financial officer and treasurer of Idenix from October 2010 to June 2011 and as the corporate controller of Idenix from March 2008 to October 2010. Before joining Idenix, Daniella Beckman held positions at Coley Pharmaceutical Group, most recently as corporate controller. Prior to Coley, Daniella Beckman also held positions at Biogen Idec from September 2004 through March 2006 as well as PricewaterhouseCoopers from September 2000 through September 2004. Daniella Beckman holds a B.A. from Boston University and is also a Certified Public Accountant (CPA).
Follow Daniella Beckman:
About Tango Therapeutics: Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Gerry Haines
Executive Vice President, Chief Financial Officer of Impulse Dynamics
Haines joined Impulse Dynamics in July 2019, bringing to the company a wealth of experience and proven track record in business, corporate finance and public markets, as well as acumen in strategic planning, M&A, and investor relations. His career has spanned a series of positions of increasing scope and responsibility. Most recently, he served as Chief Financial Officer at Mercury Systems, Inc. (NASDAQ: MRCY), where he also led Corporate Development, legal, and several other functions. Prior to Mercury, Haines served as Executive Vice President of Verenium Corporation, Executive Vice President of Strategic Affairs of Enterasys Networks, Inc., Senior Vice President of Cabletron Systems, Inc., the predecessor to Enterasys Networks; and Vice President of Applied Extrusion Technologies, Inc. Haines holds a bachelor’s degree in Business Administration, magna cum laude, from Boston University and a law degree from Cornell University.
Follow Gerry Haines:
About Impulse Dynamics: Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF).
Candice Cantelli Meklis
Chief Financial Officer of PatientsLikeMe
Candice Cantelli Meklis is the Chief Financial Officer at PatientsLikeMe.
Follow Candice Cantelli Meklis:
About PatientsLikeMe: PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform.
Grayson Allen
CFO/COO & Co-Founder of RevBio
Grayson oversees the financial planning and reporting function as Interim CFO at Maxwell Health, and is also involved in strategic and tactical matters related to Maxwell’s continued growth. Previously, Grayson served as the CFO of a venture-backed technology company where he led a team which oversaw all financial planning and reporting, accounting, information technology, and human resources functions at the company. He played a key role in raising more than $60 million in venture capital and implemented the infrastructure necessary for rapid growth. Grayson also served as CFO for a private equity owned company engaged in the design and manufacture of bridge cranes, gantry cranes, and other custom industrial material handling solutions. While there, Grayson played an instrumental role in executing a turnaround strategy which included reducing past due receivables by 71%, managing cash flow during a period of tight liquidity, renegotiating contract terms with customers and suppliers, and assisting in the recapitalization of the ownership structure. Previously, as a Principal at the $500 million private equity arm of a leading commercial bank holding company, he was a member of the team which structured and oversaw a portfolio consisting of private equity, venture capital, and fund-of-funds investments. Grayson started his career as a commercial loan underwriter. Grayson received his B.A. in History (high honors) from Dartmouth College and his M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology. Outside of work, Grayson enjoys being outdoors and active as much as possible, and likes sailing in the summer, hiking in the fall, and running throughout the year. For many years he has collected Asian art and artifacts and has been actively collecting Japanese woodblock prints since he was 12 years old. Both Grayson and his wife Lorraine enjoy cooking together and are always interested in trying out new recipes when they have the chance.
Follow Grayson Allen:
About RevBio: RevBio was started with one goal in mind—to end medicine’s 50-year search for a biocompatible bone adhesive.
Peter F. McAree
Senior Vice President, Chief Financial Officer & Treasurer of HeartWare International
Peter joined HeartWare in July 2012 as Chief Financial Officer with overall responsibility for the strategy and operations of the Company’s accounting and finance functions, as well as oversight of the Information Technology department. Peter has more than 25 years of financial management and public accounting experience, serving most recently as Senior Vice President and Chief Financial Officer of Caliper Life Sciences prior to their acquisition by PerkinElmer in November 2011. Before that, Peter served as CFO of Zymark Corporation prior to the company’s merger with Caliper in 2003. Peter is a Certified Public Accountant in Massachusetts, and holds a degree from Bentley University.
Follow Peter F. McAree:
About HeartWare International: HeartWare International develops and manufactures small implantable heart pumps or VAD for the treatment of advanced heart failure in US.
Joanne Bryce
Chief Financial Officer of Disc Medicine
Follow Joanne Bryce:
About Disc Medicine, Speedy Packets: Disc Medicine is a hematology company
Spencer Adams
Chief Financial Officer of Docent Health
Spencer Adams is the Chief Financial Officer at Docent Health.
Follow Spencer Adams:
About Docent Health: Helping health systems build and grow lasting patient relationships
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Marc Schneebaum
Chief Financial Officer of Avalyn Pharma
Follow Marc Schneebaum:
About Avalyn Pharma: Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Lynn Blake
CFO of SynerFuse
Lynn is the Chief Financial Officer of SynerFuse and Executive Vice President of State Street Global Advisors (SSGA) and CIO of Global Equity Beta Solutions. In this capacity, she oversees a team of 70 portfolio managers globally, and more than 1,600 portfolios with assets in excess of $1.4 trillion across all equity index and smart beta strategies. She also oversees SSGA’s Corporate Governance and Global Proxy Voting as well as the Company Stock Group which manages fiduciary transactions and company stock investments, including company stock ownership and 401K plans. In addition, she is a member of the SSGA Fiduciary Committee, the Investment Committee, and the IT Steering Committee. Lynn also serves as a member of SSGA’s Executive Management Group. Prior to her current role, Lynn was head of non-US markets of passive equities, responsible for overseeing the management of all non-US equity index strategies, as well as serving as portfolio manager for several equity index portfolios. She joined SSGA in 1987. Lynn has a Master of Business Administration in finance from Northeastern University, and a Bachelor of Science from the Boston College Carroll School of Management. She earned the Chartered Financial Analyst (CFA) designation and is a member of the CFA Institute and the Boston Security Analyst Society. She also serves on various index advisory boards and committees.
Follow Lynn Blake:
About State Street Global Advisors, SynerFuse: SynerFuse is a provider of traditional spine implants intended to offer long-term pain management without the use of addictive opioids
Don Munoz
Chief Financial Officer of NuCana BioMed
Don Munoz is the Chief Financial Officer at NuCana BioMed.
Follow Don Munoz:
About NuCana BioMed: NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Alfonso Hernandez-Maureta
CFO of Sincrolab
Alfonso Hernandez-Maureta is the CFO of SincroLab.
Follow Alfonso Hernandez-Maureta:
About Sincrolab: Sincrolab offers an Artificial Intelligence digital prescription neuro medicine based on videogames delivered through mobile devices.
